New Insights from Disc Medicine on Chronic Kidney Disease Treatment
New Developments in Chronic Kidney Disease Treatments
Disc Medicine, Inc. (NASDAQ:IRON), a forward-thinking biopharmaceutical company dedicated to addressing serious hematologic conditions, has exciting news to share from the 2024 American Society of Nephrology (ASN) Kidney Week. The company will unveil significant new clinical data related to its candidate drug DISC-0974, specifically targeting patients impacted by chronic kidney disease (CKD) and associated anemia.
Presentation at ASN Kidney Week
The conference, an important event for researchers and healthcare professionals in the nephrology field, is scheduled to take place in sunny San Diego. During this gathering, Disc Medicine intends to present findings from a Phase 1b study that explores the safety and efficacy of DISC-0974. This study is particularly focused on non-dialysis dependent chronic kidney disease patients who experience anemia.
Study Insights
The recent presentation will delve into safety and pharmacokinetics associated with DISC-0974, alongside its effects on hepcidin, iron levels, and anemia. As noted by John Quisel, the company's President and CEO, sharing these new data highlights their commitment to developing treatments that address the urgent needs of patients with CKD.
Details of the Presentation
Anticipation is building with the upcoming presentation, which has been assigned Abstract Number: 4126178. The study is described as a double-blind, placebo-controlled investigation into DISC-0974’s efficacy among the targeted demographic. The event is set for October 25, during the hours of 10:00 AM to 12:00 PM PST, with presentations led by Dr. Pablo Pergola.
About DISC-0974
DISC-0974 functions as an anti-hemojuvelin antibody, a groundbreaking approach to modulating iron metabolism within the body. By targeting hepcidin regulation, DISC-0974 represents a potential shift in how anemia related to CKD can be managed, thereby improving patient quality of life.
Research Goals and Future Directions
Disc Medicine's ongoing research endeavors are focused on creating innovative therapies that can positively impact hematologic health. By capitalizing on unique biological pathways related to red blood cell development and iron management, the company aims to introduce first-in-class therapeutics capable of alleviating serious conditions faced by many patients.
Commitment to Patients
With their eyes set on the future, the team at Disc Medicine is passionate about meeting patient needs and addressing the complexities of hematologic diseases. Engaging in trials like the one for DISC-0974 reflects their staunch commitment to scientific advancement and patient-centered care.
Frequently Asked Questions
What is DISC-0974 used for?
DISC-0974 is being investigated as a treatment for anemia associated with non-dialysis dependent chronic kidney disease.
When is the presentation of the data?
The presentation will occur on October 25, between 10:00 AM and 12:00 PM PST at the ASN Kidney Week conference.
Who is presenting the data?
The data will be presented by Dr. Pablo Pergola, a key figure in the research conducted on DISC-0974.
What type of study is being presented?
The study is a Phase 1b, double-blind, placebo-controlled trial focusing on the safety and pharmacokinetics of DISC-0974.
How does Disc Medicine aim to make a difference?
Disc Medicine is dedicated to discovering and developing novel treatments through an understanding of crucial biological pathways associated with red blood cell biology and iron homeostasis.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Flashpoint Announces Sponsorship of OSINT Conference at Citadel
- Global Diagnostic Testing Market Expected to Reach $272.98 Billion
- Alliance Witan PLC's Shareholder Management Insights 2024
- Aptelligence Achieves Prestigious Gold Partnership with OneStream
- Stonehage Fleming Wins Impact Award for Digital Innovation Success
- Revolutionizing Advertising: LoopMe Unveils AI Tool for Brands
- Innovative AI Education Grants by Chan Zuckerberg Initiative
- US Producer Prices Stabilize in September Amid Inflation Watch
- Celebrating Creativity at the 2024 Hollyland WE CONNECT Event
- Recent Decline in Consumer Confidence Signals Economic Concerns
Recent Articles
- Exciting Updates on DISC-0974 for Chronic Kidney Disease Patients
- Sylvamo's Upcoming Earnings Release and Webcast Details
- Alignment Healthcare Achieves High Star Ratings for 2025 Plans
- Inspirational Lineup Announced for Crypto Content Creation
- InnovAge Announces Upcoming Innovations for Elderly Care
- MaxCyte Announces Upcoming Financial Release and Call Details
- Unity Software to Present Q3 2024 Financial Results Online
- Baird Medical Reports Strong Growth in Preliminary Financials
- Auron Therapeutics Set to Shine at Upcoming Medical Retreat
- European DataWarehouse Celebrates Excellence in Data Quality
- EveryMatrix Acquires Majority Stake in Fantasma Games
- Assertio Holdings Joins 2024 Healthcare Virtual Summit
- Lazard Readies for Financial Results Announcement This Fall
- Compassionate Support for Hurricane Victims in Storage Needs
- Growth Forecast for Enteral Feeding Devices Market Until 2031
- WisdomTree Plans Q3 Results Conference Call for Investors
- Zaxby's Expands into Maryland with New Chicken Locations
- Exploring Growth Opportunities at Indigenomics on BAY STREET
- ESET Canada Strengthens Ties with Calgary Flames for Three More Years
- Bladex Announces Third Quarter 2024 Earnings Call Details
- Similarweb Shines as Alternative Data Provider of the Year
- Impact of Lithium Mine Closure on Battery Metal Prices
- Empowering Girls: Game Changers Initiative by BBBSA
- Rio Tinto's Jadar Project Thrives Despite Parliamentary Debate
- The Home Depot Foundation Boosts Hurricane Relief Commitment
- Wells Fargo's Q3 Profit Decline Amid Squeezed Interest Income
- CoreWeave Secures $650 Million Credit Facility to Propel Growth
- Evolent Health's 2024 Financial Update and Investor Events
- Understanding Medicare Enrollment Scams and How to Avoid Them
- Wells Fargo Adjusts Flywire Rating Amid Market Concerns
- Bank7 Corp. Reports Impressive Q3 2024 Earnings Results
- Toronto-Dominion Bank Faces Challenges Amid RBC Downgrade
- Scholar Rock Gains Momentum Following Strong Clinical Trial Results
- A. O. Smith Adjusts Earnings Expectations Amid Market Changes
- Tyra Biosciences Innovations At The EORTC-NCI-AACR Symposium
- Tesla's Robotaxi Showcase: Maintain Hold Rating Insights
- Mark Dorsey Appointed as Chief Revenue Officer at Appian
- Wynn Resorts Shows Growth Potential with Al Marjan Project
- ThinkCERCA Accelerates Education Tech with $250,000 Win
- Piper Sandler Raises AMD Price Target to $200 Amid Growth
- Piper Sandler Holds Neutral on ULTA Beauty Amid Valuation Pressures
- Mizuho Maintains Neutral Rating on Antero Resources Outlook
- Mizuho's Insights on Delek US Holdings and Market Challenges
- Impact of US Election Dynamics on Global Markets
- Tesla Faces Challenges in Sweden Amid Union Disruptions
- Fastenal Reports Strong Quarterly Results Amid Safety Demand
- U.S. Economy Thrives Amidst Recession Doubts and Optimism
- Top Dividend Picks for Growth: Amgen and Hormel Foods
- JPMorgan's Third Quarter Results Show Resilience Amid Challenges
- Energy Recovery Ventilator Market Forecasts a Bright Future